Future studies on the identification and generation of neutralizing antibodies against AnxA1, currently under development, will provide us the opportunity to validate novel therapeutic approaches for the treatment of multiple sclerosis that target AnxA1 expression or function. The gene discussed is ANXA1; the disease is multiple sclerosis.